3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
9
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Breast Neoplasms
993
Neoplasms
852
Carcinoma, Non-Small-Cell Lung
845
Prostatic Neoplasms
528
Neoplasm Metastasis
501
Leukemia, Myeloid, Acute
489
Melanoma
456
Colorectal Neoplasms
447
Multiple Myeloma
441
Lung Neoplasms
422
Pancreatic Neoplasms
353
Recurrence
350
Lymphoma
350
Ovarian Neoplasms
341
Lymphoma, Non-Hodgkin
329
Leukemia
324
Leukemia, Lymphocytic, Chronic, B-Cell
302
Precursor Cell Lymphoblastic Leukemia-Lymphoma
271
Carcinoma, Renal Cell
256
Head and Neck Neoplasms
246
Brain Neoplasms
245
Carcinoma, Hepatocellular
234
Glioblastoma
232
Squamous Cell Carcinoma of Head and Neck
231
Myelodysplastic Syndromes
231
Lymphoma, Large B-Cell, Diffuse
228
Lymphoma, Follicular
219
Colonic Neoplasms
191
Stomach Neoplasms
182
Rectal Neoplasms
175
Interventions
rasburicase
2
Urate Oxidase
1
Allopurinol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Interventional
×
Hyperuricemia
×
Clear all
NCT00607152
2014-05-08
Rasburicase (Fasturtec) Registration Trial
Sanofi
Phase 3
Terminated
10 enrolled
NCT00664144
2012-03-07
GRAAL2
Sanofi
Phase 2
Terminated
33 enrolled